| Biologic Therapy |
1 |
0.85 |
| Monoclonal Antibody |
0 |
0.57 |
| Multiple Sclerosis |
0 |
0.48 |
| Meta-Analysis |
0 |
0.41 |
| Health Care Reform |
0 |
0.4 |
| Clinical Research |
0 |
0.33 |
| Disability |
0 |
0.33 |
| Rare Diseases |
0 |
0.33 |
| Food and Drug Administration (FDA) |
0 |
0.25 |
| Herpes Simplex |
0 |
0.24 |
| Meningococcal Disease |
0 |
0.21 |
| Revenue and Practice Management |
0 |
0.19 |
| Antineoplastic Drug |
0 |
0.16 |
| Grant |
0 |
0.16 |
| Infectious Mononucleosis |
0 |
0.16 |
| Neuromyelitis Optica |
0 |
0.16 |
| Outpatient Clinic |
0 |
0.16 |
| Medical Life |
0 |
0.12 |
| Meningococcal Meningitis |
0 |
0.12 |
| Social Determinants of Health |
0 |
0.12 |
| Adherence |
0 |
0.08 |
| Arizona |
0 |
0.08 |
| Bacteria |
0 |
0.08 |
| Board Certification |
0 |
0.08 |
| California |
0 |
0.08 |
| Central Nervous System |
0 |
0.08 |
| Clinician Health and Well-Being |
0 |
0.08 |
| Dorsum |
0 |
0.08 |
| Emesis |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Health Care Quality, Access, and Evaluation |
0 |
0.08 |
| Hypogammaglobulinemia |
0 |
0.08 |
| Immunosuppressive Therapy |
0 |
0.08 |
| Insurance |
0 |
0.08 |
| Meningitis |
0 |
0.08 |
| Minnesota |
0 |
0.08 |
| Oregon |
0 |
0.08 |
| Peer Review |
0 |
0.08 |
| Quality of Life |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Statistics |
0 |
0.08 |